Search

This volume reviews current and potential future therapies for arrhythmias. It is a highly practical guide for the use of pharmaceuticals in the management of the discipline, and has been written in a simple quick-access format.Antiarrhythmic Drugs builds on the current understanding of pathophysiological mechanisms and insights gained from previous studies of therapeutic interventions. It is designed to establish the baseline level of knowledge that a cardiovascular professional needs to know on a day-to-day basis.

This book considers paradigmatic clinical cases in order to cast light on key issues relating to elective or emergency stent implantation and the use of oral anticoagulation (OAC) in patients with atrial fibrillation. The topics addressed include the optimal periprocedural antithrombotic treatment (uninterrupted vs interrupted OAC, intraprocedural use of heparin and glycoprotein IIb/IIIa inhibitors, etc.), the most appropriate type of stent (bare metal vs drug eluting vs “bioactive”), the optimal regimen (e.g., triple therapy of OAC, aspirin, and clopidogrel vs the combination of OAC and a single antiplatelet agent), and the most suitable duration of the antithrombotic treatment prescribed at discharge (1 vs 6–12 months). The case-based management recommendations will be of wide practical value in the current health care context, where percutaneous coronary intervention is available even to patients with relevant co-morbidities, such as those warranting long-term OAC, and the indications for OAC are much broader than in the past. The book will appeal especially to clinical and interventional cardiologists, internal medicine specialists, hematologists, and family physicians and will also be of interest to cardiology and internal medicine residents and fellows.

Bayés'syndrome refers to the association between interatrial block and supraventricular arrhythmias—mainly the occurrence of atrial fibrillation. It is also a risk factor for cardio-embolic stroke. Rapid recognition by analyzing characteristic patterns in the surface ECG will help the physician to closely monitor the patient for atrial fibrillation and decide on anticoagulation therapy if the clinical risk of stroke is increased. Interatrial blocks were described several decades ago; however, they are now gaining the attention of the medical community as a means of helping to identify patients at high risk of developing atrial fibrillation and/or cardio-embolic stroke. I welcome all readers to navigate this book and to become familiar with this concept that is helping to renovate our models of predicting atrial fibrillation and stroke.

Dieser Leitfaden soll den Leser praxisorientiert und in der notwendigen Kürze bei der Behandlung der Patienten mit dem Faktor-Xa-Inhibitor Rivaroxaban unterstützen.

This handbook offers timely investigation of current pharmaceutical trends, clinical guidelines, novel treatments, and ongoing pipeline developments, including ground-breaking advances in the use of novel oral anticoagulants. ​Atrial fibrillation (AF) affects an estimated 1–2% of the population and is the most common cause of sustained cardiac arrhythmia. Critically, the number of patients developing AF is expected to double in the next five decades, leading to increased incidence of stroke, heart failure and other serious thromboembolic events.

This issue of Interventional Cardiology Clinics examines approaches to left atrial appendage exclusion. Topics include stroke and bleeding risks in patients with atrial fibrillation, embryology and anatomy, rationale, catheter-based endocardial closure, pericardial access, catheter-based epicardial closure, surgical closure, device and left atrial appendage specific characteristic for successful closure, clinical results, the role of CTA and MRA imaging, imaging with TEE, post-procedural management, and prevention and management of complications.

Atrial fibrillation is rapidly assuming a predominant role in current vascular medicine. Parallel to its escalating prevalence, due mainly to the global aging of the population, physicians worldwide and across different medical fields have joined efforts producing dramatic breakthroughs in diagnostics and the multidimensional therapeutic arsenal to this common arrhythmia. In this endeavor, we aim to cover an updated and practical overview of the whole spectrum of this disturbing hurdle. Firstly, this publication will encompass different perspectives for the same entity: atrial fibrillation, encompassing the first line approach of Internal Medicine and the mindset of cardiologists and neurologists. Thereafter, an updated look on the epidemiology that has been exponentiating the awareness on this arrhythmia with a special scrutiny to the impact on stroke units worldwide is discussed. In the next section, the main advances in the diagnostic area will be presented, ranging from the anatomical viewpoint to rhythm disturbances and embolic complications. The medical and interventional treatment will follow with critical reviews of the therapeutic outbreaks and achievements into a practical modern-day care. In summary, we designed a flow of contents from the burden of the disease to its approach, with the intent to provide an updated, comprehensive overview of all major current dilemmas in atrial fibrillation conceptualized for physicians from all specialties addressing patients with this contemporary clinical challenge. (Imrint: Nova Biomedical)

The paradigm for atrial fibrillation (AF) management has changed significantly in recent years. A new era has begun for the prevention of one of the most tremendous complication of AF, stroke. Prevention of ischemic stroke in AF patients with oral anticoagulants represents a huge challenge because of the narrow therapeutic change of these drugs, interindividual and intraindividual variability, and the unsatisfactory time in therapeutically range (TTR) with this type of medication.New guidelines have emerged as a result of new mechanisms for initiation and perpetuation for pharmacotherapy to cure AF and trials with new classes of antithrombotic drugs are ongoing. The treatment of AF is still in its infancy, but recent research is revealing how it can be applied with optimal efficacy. This book assists trainees, recertifying physicians, practicing physicians and other professional staff in internal medicine, cardiology, emergency medicine, and clinical pharmacology to apply new diagnostic tools for selecting the best treatment options for AF patients.

Advancements in the treatment and prevention of Atrial Fibrillation are presented in this important new book. Atrial Fibrillation affects approximately 2.5 million individuals in the United States and is projected to affect 15 million individuals by 2050. In Atrial Fibrillation: From Bench to Bedside, the reader is provided with the latest information that is critically important in the daily care and for the potential cure of patients with Atrial Fibrillation. Each chapter deals with a different aspect of Atrial Fibrillation and was authored by internationally recognized experts in the evolving field of cardiac electrophysiology. This book is a single source that provides a multi-perspective look at and approach to Atrial Fibrillation. Because Atrial Fibrillation is so prevalent and affects all areas of medicine, the information in this book will be useful to cardiologists, cardiac surgeons, researchers, and all those in the medical field.